Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zometa,ZometaStudy001,2021,USA,MDV,350,68,65,35,27.5,28,85,12,15,35,30,20,55,25,15,5,20,40,30,18,7,4,9,3,22,48,55,AC,Taxol,CMF,Taxol,25,35,20,15,60,70,15,45,40,60,2
Zometa,ZometaStudy002,2022,Canada,Claim Database,420,72,70,30,28.1,25,80,15,18,32,28,22,50,28,17,5,18,38,34,20,8,5,10,4,25,50,60,AC-T,FEC,AC,Docetaxel,28,32,18,18,65,75,12,48,40,65,3
Zometa,ZometaStudy003,2023,UK,MDV,280,65,60,40,26.8,30,90,10,20,40,25,15,60,20,15,5,25,45,25,15,6,3,8,2,20,45,50,EC,CMF,FEC,Docetaxel,22,38,25,12,55,65,18,42,40,70,2.5
Zometa,ZometaStudy004,2023,Australia,Claim Database,480,70,68,32,29.0,22,82,13,16,34,29,21,52,26,16,6,19,39,32,19,7,4,9,3,23,49,58,AC-T,FEC,AC,Docetaxel,26,34,19,17,62,72,14,46,40,63,2.8
